Literature DB >> 10204753

Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat.

M J Field1, S McCleary, J Hughes, L Singh.   

Abstract

A single injection of streptozocin (50 mg/kg, i.p.) led to the development of static and dynamic allodynia in the rat. The two responses were detected, respectively, by application of pressure using von Frey hairs or lightly stroking the hind paw with a cotton bud. Static allodynia was present in the majority of the animals within 10 days following streptozocin. In contrast, dynamic allodynia took almost twice as long to develop and was only present in approximately 60% of rats. Morphine (1-3 mg/kg, s.c.) and amitriptyline (0.25-2.0 mg/kg, p.o.) dose-dependently blocked static allodynia. However, neither of the compounds was effective against dynamic allodynia. In contrast, gabapentin (10-100 mg/kg, p.o.) and the related compound pregabalin (3-30 mg/kg, p.o.) dose-dependently blocked both types of allodynia. However, the corresponding R-enantiomer (10-100 mg/kg, p.o.) of pregabalin, was found to be inactive. The intrathecal administration of gabapentin dose-dependently (1-100 microg/animal) blocked both static and dynamic allodynia. In contrast, administration of similar doses of gabapentin into the hind paw failed to block these responses. It is suggested that in this model of neuropathic pain dynamic allodynia is mediated by A beta-fibres and the static type involves small diameter nociceptive fibres. These data suggest that gabapentin and pregabalin possess a superior antiallodynic profile than morphine and amitriptyline, and may represent a novel class of therapeutic agents for the treatment of neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10204753     DOI: 10.1016/s0304-3959(98)00239-5

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  56 in total

1.  Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity.

Authors:  M J Field; R J Oles; L Singh
Journal:  Br J Pharmacol       Date:  2001-01       Impact factor: 8.739

2.  The use of clinical trial simulation to support dose selection: application to development of a new treatment for chronic neuropathic pain.

Authors:  Peter A Lockwood; Jack A Cook; Wayne E Ewy; Jaap W Mandema
Journal:  Pharm Res       Date:  2003-11       Impact factor: 4.200

Review 3.  Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.

Authors:  S Vink; P F Alewood
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

Review 4.  Pregabalin: in the treatment of postherpetic neuralgia.

Authors:  James E Frampton; Rachel H Foster
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  alpha2delta ligand: a new, smart pill for visceral pain in patients with hypersensitive irritable bowel syndrome?

Authors:  Michael Camilleri
Journal:  Gut       Date:  2007-10       Impact factor: 23.059

6.  Calcium channel α2δ1 proteins mediate trigeminal neuropathic pain states associated with aberrant excitatory synaptogenesis.

Authors:  Kang-Wu Li; Yanhui Peter Yu; Chunyi Zhou; Doo-Sik Kim; Bin Lin; Kelli Sharp; Oswald Steward; Z David Luo
Journal:  J Biol Chem       Date:  2014-01-23       Impact factor: 5.157

7.  Further evidence for the role of the alpha(2)delta subunit of voltage dependent calcium channels in models of neuropathic pain.

Authors:  M J Field; J Hughes; L Singh
Journal:  Br J Pharmacol       Date:  2000-09       Impact factor: 8.739

Review 8.  Targeting voltage-gated calcium channels for neuropathic pain management.

Authors:  Danielle Perret; Z David Luo
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

9.  Antiallodynic effect of pregabalin in rat models of sympathetically maintained and sympathetic independent neuropathic pain.

Authors:  Dong Woo Han; Tae Dong Kweon; Jong Seok Lee; Youn-Woo Lee
Journal:  Yonsei Med J       Date:  2007-02-28       Impact factor: 2.759

Review 10.  Pregabalin: in the treatment of postherpetic neuralgia.

Authors:  Kate McKeage; Susan J Keam
Journal:  Drugs Aging       Date:  2009       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.